EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual PI3K / AKT and CDK4 /6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model

Monika Lukoseviciute, Madeleine Birgersson, Paolo Ceriani, Margareta Wilhelm, Ourania N Kostopoulou iD

Molecular Oncology · 2026-07 · 20 (7) · 1800-1813

DOI: 10.1002/1878-0261.70230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 24.02.2026. Verfasst von Monika Lukoseviciute und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4, Proto-Oncogene Proteins c-akt, Medulloblastoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eva and Oscar Ahréns Foundation, Swedish Cancer Foundation, Robert Lundbergs Minnesstiftelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medulloblastoma (MB) is a brain tumor for which current treatments cause serious side effects and are not curative for all patients, highlighting the need for more effective and brain‐protecting therapies. Recently, we combined phosphoinositide 3‐kinase (PI3K) inhibitor (BYL719), fibroblast growth factor receptor (FGFR) inhibitor (JNJ‐42756493) and cyclin‐dependent kinase (CDK)4/6 inhibitor (PD‐0332991) in MB cell lines, and discovered synergistic effects. In the current study, we investigate the most efficient therapies in a normal/tumorigenic neural stem cell model. A sonic hedgehog (SHH)‐MB model, including a Gorlin syndrome patient neuroepithelial stem cell line (NES) and its tumor derivative (tNES), was used to evaluate single and combined treatments of PI3K, AKT, FGFR, and CDK4/6 inhibitors (BYL719, AZD5363, JNJ‐42756493, and PD‐0332991, respectively). Effects on viability, cell confluence and apoptosis were tested on NES and tNES cells cultured as 2D monolayers and 3D spheroids. We found that 2D tNES cells were generally more sensitive to the inhibitory effects of both single and combination treatments compared to 2D NES cells. In the 3D setting, all single drugs were more effective against tNES than NES, except for JNJ‐42756493, which showed the opposite trend. Drug combinations in 3D cultures generally resulted in synergistic or additive effects on cell viability in NES and tNES. This study illustrates that single and combined administrations of PI3K, FGFR, CDK4/6, and AKT inhibitors in a NES/tNES model have dose‐dependent and additive/synergistic anti‐MB activity impacting tumor growth. Their effects on tNES cells were generally more pronounced than on NES; however, the difference in proliferative capacity between the cells should be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Proto-Oncogene Proteins c-aktMedulloblastomaNeoplastic Stem CellsHedgehog ProteinsPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsCerebellar NeoplasmsHumansCell Line, TumorPhosphatidylinositol 3-KinasesPiperazinesPyridinesCell ProliferationCell SurvivalPyrimidines

Stichwörter der Autor:innen

AKT inhibitorsCDK4/6 inhibitorsMedulloblastomaNeuroepithelial stem cellsPI3K inhibitorstargeted therapy

Substanzen

Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Proto-Oncogene Proteins c-aktHedgehog ProteinsPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsPhosphatidylinositol 3-KinasesPiperazinesPyridinesCDK6 protein, human

Autor:innen und Institutionen

  • Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Ourania N Kostopoulou

Förderung

  • Eva and Oscar Ahréns Foundation
  • Swedish Cancer Foundation
  • Robert Lundbergs Minnesstiftelse
  • Stockholm Cancer Society
  • Anna Brita and Bo Castegren's Memory
  • Gunvor and Josef Aners Foundation
  • Magnus Bergvalls Foundation

Zitieren

APA

Lukoseviciute, M., Birgersson, M., Ceriani, P., Wilhelm, M., & Kostopoulou, O. N. (2026). Dual PI3K / AKT and CDK4 /6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model. Molecular Oncology, 20(7), 1800-1813. https://doi.org/10.1002/1878-0261.70230

Vancouver

Lukoseviciute M, Birgersson M, Ceriani P, Wilhelm M, Kostopoulou ON. Dual PI3K / AKT and CDK4 /6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model. Molecular Oncology. 2026;20(7):1800-1813. doi:10.1002/1878-0261.70230

BibTeX
@article{Lukoseviciute2026,
  author = {Lukoseviciute, Monika and Birgersson, Madeleine and Ceriani, Paolo and Wilhelm, Margareta and Kostopoulou, Ourania N},
  title = {Dual PI3K / AKT and CDK4 /6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {7},
  pages = {1800--1813},
  doi = {10.1002/1878-0261.70230}
}
Kostenlos starten →